Search our science

Search our scientific publications and resources
on rare bleeding disorders

Study Phase
Content Type

Scientific resources from Novo Nordisk

Novo Nordisk supports sharing of the scientific research on our molecules. The search results below include peer-reviewed articles that are authored by Novo Nordisk employees or are funded by Novo Nordisk, as well as congress abstracts, posters and presentations, and also related educational resources.


Search Results

We found 383 resources matching your search criteria

Shapiro A, Castaman G, Cepo K, Hollensen C, Matsushita T, Hvitfeldt Poulsen L, Young G, Zupancic-Salek S, Jiménez-Yuste V,. Efficacy and safety of subcutaneous prophylaxis with concizumab in patients with haemophilia A or B with inhibitors: Results from explorer4, a phase 2, randomised, open-label, controlled trial. Blood. 2019;134(Suppl 1 ):1139.
Oral presentation
Kjellev SL, Østergaard H, Greisen PJ, Hermit MB, Thorn K,Hansen BG, Zhou R, Bjelke JR, Kjalke M, Stavenuiter F, Lund J, Holm TL, Ley CD, Elenius D, Holmberg H, Thygesen P, Loftager M, Rasch MG, Lorenzen N, Gandhi PS, Lamberth K, Egebjerg T, Lund S, Henriksen A, Rahbek-Nielsen H, Yang Z and Hilden I. A Next-Generation FVIII Mimetic Bispecific Antibody. American Society of Hematology - 61st Annual Meeting. 2019.
Oral presentation
Deguchi A on behalf of authors Giangrande P, Chowdary P, Ehrenforth S, Hanabusa H, Leebeek FWG, Nemes L, Poulsen LH, Santagostino E, You CW, Clausen WHO, Oldenburg J. Clinical evaluation of novel recombinant glycoPEGylated FVIII (turoctocog alfa pegol, N8-GP): Efficacy and safety in previously treated patients with severe haemophilia A – results of the pathfinder 2 international trial [encore]. Japanese Society of Pediatric Hematology/Oncology - 61st Annual Meeting. 2019.
Oral presentation
Ogura on behalf of authors Chowdary P, Carcao M, Clausen WHO, Holme P, Moss J, Tosetto A, Wheeler A, Santagostino E. Simple and fixed N8-GP dosing regimen associated with measurable trough levels and low annualised bleed rates in children and adolescents/adults treated with N8-GP prophylaxis. Japanese Society of Pediatric Hematology/Oncology - 61st Annual Meeting. 2019.
Kjellev S, Østergaard H, Greisen PJ, Hermit MB, Thorn K, Hansen BG, Zhou R, Zhiru Y, Bjelke JR, Kjalke M, Lund J, Holm TL, Ley CD, Madsen DE, Thygesen P, Loftager M, Gandhi P, Lamberth K, Rasch MG, Egebjerg T, Lund S, Lorenzen N, Henriksen A, Rahbek-Nielsen H, Hilden I. A next-generation FVIII mimetic bi-specific antibody - potently restores the hemostatic capacity in hemophilia A settings in vitro and in vivo. Blood. 2019;134(Supplement 1):96.
Shashikant Apte; Aby Abraham; Prantar Chakrabarti; Trine Hansen; Naresh Gupta; M Joseph John; Cecil Ross; S. Chandrakala; Tulika Seth; Neeraj Sidharthan; Anne Louise Tølbøll Sørensen. guardian 10: post-approval safety study of turoctocog alfa in previously treated patients with haemophilia A in India. Indian Society of Haematology and Blood Transfusion - 60th Annual Conference (Haematocon 2019). 2019.
Primary manuscript
Buranahirun C, Walsh KS, Mrakotsky-Ladendorf C, Croteau SE, Rajpurkar M, Kearney S, Hannnemann C, Wilkening GN, Shapiro K, Cooper D. Cognitive and behavioral function in children and young adults with hemophilia: a 25-year journey from the Hemophilia Growth and Development Study to the eTHINK study. Pediatr Blood Cancer. 2019;e28004.

This website is intended
for healthcare professionals (HCPs)
outside of the U.S.

Take me to